Abdominal Doppler Ultrasound

Apr 5th, 2014

Houston, TX

US

https://store2.aheconline.com/index.php?route=product/product&path=59_83_166&product_id=963

Topics include an overview of physics and instrumentation, anatomy and hemodynamics, and diagnostic criteria. This course can be taken individually as a two-day course or as part of the Vascular Ultrasound seven-day course.

PET reveals brain receptor deficits in schizophrenia

June 4, 2026

Caption: Representative images show emphysema and functional lung maps derived by CT and PREFUL-MRI: (A–C) CT-derived emphysema images, (D–F) perfusion maps, (G–I) regional ventilation maps, (J–L) flow-volume loop correlation metric maps, (M–O) ventilation/perfusion combined parameter maps. (A, D, G, J, M) Images in a 63-year-old male with normal spirometry: FEV1%pred = 89.0%, FEV1/FVC = 0.73; emphysema percentage = 0.2%, QDP = 7%, VDPRVent = 2%, VDPFVL-CM = 1%. (B, E, H, K, N) Images in a 65-year-old female with PRISm + RP: FEV1%pred = 71.2%, FVC %pred = 76.8%, FEV1/FVC = 0.76; emphysema percentage = 4.7%, QDP = 10%, VD-PRVent = 18%, VDPFVL-CM = 6%. (C, F, I, L, O) Images in a 57-year-old male with AO: FEV1%pred = 56.8%, FEV1/FVC = 0.52; emphysema = 11.1%, QDP = 31%, VDPRVent = 33%, VDPFVL-CM = 41%. AO = airflow obstruction, FEV1 = forced expiratory volume in 1 second, FVC = forced vital capacity, FVL-CM = flow-volume loop correlation metric, %pred = percent predicted, PREFUL = phase-resolved function lung, PRISm = preserved ratio impaired spirometry, QDP = perfusion defect percentage, RVent = regional ventilation, VDP = ventilation defect percentage.

MRI finds perfusion defects across a range of lung impairments

June 4, 2026

AI for CT & PET/CT Imaging

AI for CT & PET/CT Imaging

June 4, 2026

Lab Equipment Drug Manufacturing

Radiopharmaceutical manufacturers report uneven FDA inspections

June 4, 2026

PET reveals brain receptor deficits in schizophrenia

The study confirms that deficits in M1 receptor are present in a subgroup of schizophrenia patients.

June 4, 2026

MRI finds perfusion defects across a range of lung impairments

By Kate Madden Yee

Impaired lung function is associated with increased pulmonary perfusion defects detectable by a particular MRI technique.

June 4, 2026

Caption: Representative images show emphysema and functional lung maps derived by CT and PREFUL-MRI: (A–C) CT-derived emphysema images, (D–F) perfusion maps, (G–I) regional ventilation maps, (J–L) flow-volume loop correlation metric maps, (M–O) ventilation/perfusion combined parameter maps. (A, D, G, J, M) Images in a 63-year-old male with normal spirometry: FEV1%pred = 89.0%, FEV1/FVC = 0.73; emphysema percentage = 0.2%, QDP = 7%, VDPRVent = 2%, VDPFVL-CM = 1%. (B, E, H, K, N) Images in a 65-year-old female with PRISm + RP: FEV1%pred = 71.2%, FVC %pred = 76.8%, FEV1/FVC = 0.76; emphysema percentage = 4.7%, QDP = 10%, VD-PRVent = 18%, VDPFVL-CM = 6%. (C, F, I, L, O) Images in a 57-year-old male with AO: FEV1%pred = 56.8%, FEV1/FVC = 0.52; emphysema = 11.1%, QDP = 31%, VDPRVent = 33%, VDPFVL-CM = 41%. AO = airflow obstruction, FEV1 = forced expiratory volume in 1 second, FVC = forced vital capacity, FVL-CM = flow-volume loop correlation metric, %pred = percent predicted, PREFUL = phase-resolved function lung, PRISm = preserved ratio impaired spirometry, QDP = perfusion defect percentage, RVent = regional ventilation, VDP = ventilation defect percentage.

AI detects lung cancer nodules well but shows low specificity

By Kate Madden Yee

The finding suggests the models offer “a potential role as adjunctive tools for ruling out malignancy” rather than classifying it.

June 4, 2026

Am 2020 06 26 16 29 2945 Cancer Lung 400

Radiopharmaceutical manufacturers report uneven FDA inspections

RMTA lays out radiopharmaceutical regulatory and payment policy issues.

June 4, 2026

Lab Equipment Drug Manufacturing

AI-driven cardiac PET attenuation correction shows promise

By Kate Madden Yee

The algorithm could offer a “practical alternative in cardiac PET,” researchers noted.

June 3, 2026

Cardiac stress test imaging comparison showing DeepAC and CT-based attenuation correction scans for two patients with quantitative perfusion data.

Image-guided focal laser ablation effective for prostate cancer

By Amerigo Allegretto

MRI-directed, ultrasound-guided TPLA may be a promising technique to treat prostate cancer while avoiding radical therapies.

June 3, 2026

Preablation, postablation, and recurrence multiparametric MRI scans depict a 63-year-old man treated with transperineal focal laser ablation (TPLA) for localized prostate cancer. Clinical parameters included an initial prostate-specific antigen (PSA) level of 7.2 ng/mL, a Prostate Imaging Reporting and Data System (PI-RADS) grade 4 lesion (red circles) in the right apical peripheral zone, and a maximum tumor length of 5 mm. MRI-guided targeted biopsy confirmed a Gleason score 3+4 prostate cancer tumor. (A) Pre-ablation axial T2-weighted MRI scan and apparent diffusion coefficient (ADC) image shows the apical PI-RADS 4 lesion (circles). (B) Six-month post-ablation axial T2-weighted MRI scan and ADC image show cystic necrosis (arrows). There was no evidence of recurrence; the PSA level was 1.5 ng/mL. (C) One-year after ablation, the patient’s PSA level had increased to 4.3 ng/mL. Axial T2-weighted MRI scan and the ADC image shows a recurrent lesion (blue circles) in the right apical peripheral zone adjacent to the ablation scar. Targeted biopsy confirmed Gleason score 3+4 prostate cancer, which was classified as in-field recurrence of clinically significant prostate cancer and subsequently re-treated with TPLA. In summary, serial multiplanar MRI demonstrates treatment response after TPLA with post-ablation necrosis, followed by MRI-detected IFR confirmed with biopsy at 12-month follow-up. Multiparametric MRI was performed with a 3.0-T MRI scanner (Skyra; Siemens Healthineers) using T2-weighted, diffusion-weighted, and ADC sequences, with gadobenate dimeglumine contrast material administration (Bracco Diagnostics).

ASCO: With help from AI, interventions boost lung cancer screening

By Erik L. Ridley

Screening rate increased sharply over six years at the 17-hospital health system.

June 3, 2026

Philips Interactive Multimedia Reporting: Where Insight Meets Impact

By Philips Healthcare Informatics

Radiology is no longer just about what you see, it’s about how effectively you communicate it.

June 2, 2026

2260299 Philips 01 Aunt Minnie Leadgen Newsletter Banner 300x250 Static

Radiologists estimate time savings with advanced radiology reports

Survey-driven insights into the impact of interactive multimedia reporting, plus practical tips to take forward when planning to implement a system.

June 2, 2026

David Vining Md Anderson Longitudinal Record Imr 2026

Interactive multimedia radiology reporting improves physician consults

Radiologists and referring physicians who are successfully using IMR advanced radiology reporting share their perspectives.

June 2, 2026

Adobe Stock 1568461586 Fizkes

SNMMI: PET reveals new brain activity in multiple sclerosis

Understanding how and where certain brain connections are lost can help explain the symptoms patients experience.

June 2, 2026

Representative SV2A PET images comparing synaptic density in healthy and disease states. The left panel shows F-18 SynVesT-1 PET distribution volume (VT) maps of the brain and spinal cord in a naïve control mouse and a mouse with experimental autoimmune encephalomyelitis (EAE), a model of multiple sclerosis. The right panel shows Cu-11 UCB-J PET images of the brain of a 46-year-old male healthy control (left) and 43-year-old female MS patient (right).

SNMMI: New PET platform guides real-time bone cancer margin assessment

By Kate Madden Yee

The approach has the potential to reshape surgical practice for osteosarcoma by allowing for precise tumor resection.

June 2, 2026

(A-C) Representative whole-body maximum-intensity projection images and regional fused PET/CT images from three histologically confirmed osteosarcoma patients who underwent paired [68Ga]Ga-B7-H3-BCH PET/CT and 18F-FDGE PET/CT within seven days. (D) Multimodal imaging evaluation of Patient Three, including x-ray, MRI (T2-weighted imaging, T2WI), CT, and B7-H3 PET/CT.

Page 1 of 231